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I. General Considerations and Scope
The previous guideline for the use of echocardiography was
published in March 1997. Since that time, there have been
significant advances in the technology of echocardiography
and growth in its clinical use and in the scientific evidence
leading to recommendations for its proper use.
Each section has been reviewed and updated in evidence
tables, and where appropriate, changes have been made in
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recommendations. A new section on the use of intraoperative
transesophageal echocardiography (TEE) is being added to
update the guidelines published by the American Society of
Anesthesiologists and the Society of Cardiovascular Anesthe-
siologists. There are extensive revisions, especially of the
sections on ischemic heart disease; congestive heart failure,
cardiomyopathy, and assessment of left ventricular (LV)
function; and screening and echocardiography in the critically
ill. There are new tables of evidence and extensive revisions
in the ischemic heart disease evidence tables.
Because of space limitations, only those sections and
evidence tables with new recommendations will be printed in
this summary article. Where there are minimal changes in a
recommendation grouping, such as a change from Class IIa to
Class I, only that change will be printed, not the entire set of
recommendations. Advances for which the clinical applica-
tions are still being investigated, such as the use of myocar-
dial contrast agents and three-dimensional echocardiography,
will not be discussed.
The original recommendations of the 1997 guideline are
based on a Medline search of the English literature from 1990
to May 1995. The original search yielded more than 3000
references, which the committee reviewed. For this guideline
update, literature searching was conducted in Medline, EM-
BASE, Best Evidence, and the Cochrane Library for English-
language meta-analyses and systematic reviews from 1995
through September 2001. Further searching was conducted
for new clinical trials on the following topics: echocardiog-
raphy in adult congenital heart disease, echocardiography for
evaluation of chest pain in the emergency department, and
intraoperative echocardiography. The new searches yielded
more than 1000 references that were reviewed by the writing
committee.
This document includes recommendations for the use of
echocardiography in both adult and pediatric patients. The
pediatric guidelines also include recommendations for
fetal echocardiography, an increasingly important field.
The guidelines include recommendations for the use of
echocardiography in both specific cardiovascular disorders
and the evaluation of patients with frequently observed
cardiovascular symptoms and signs, common presenting
complaints, or findings of dyspnea, chest discomfort, and
cardiac murmur. In this way, the guidelines will provide
assistance to physicians regarding the use of echocardio-
graphic techniques in the evaluation of such common
clinical problems.
The recommendations concerning the use of echocardiog-
raphy follow the indication classification system (eg, Class I,
II, and III) used in other American College of Cardiology/
American Heart Association (ACC/AHA) guidelines:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is useful and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the useful-
ness/efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is
not useful/effective and in some cases may be
harmful.
Evaluation of the clinical utility of a diagnostic test such as
echocardiography is far more difficult than assessment of the
efficacy of a therapeutic intervention because the diagnostic
test can never have the same direct impact on patient survival
or recovery. Nevertheless, a series of hierarchical criteria are
generally accepted as a scale by which to judge worth (1–3).
Hierarchical Levels of Echocardiography Assessment
● Technical capacity
● Diagnostic performance
● Impact on diagnostic and prognostic thinking
● Therapeutic impact
● Health-related outcomes
Because there are essentially no randomized trials assess-
ing health outcomes for diagnostic tests, the committee has
not ranked the available scientific evidence in an A, B, and C
fashion (as in other ACC/AHA documents) but rather has
compiled the evidence in tables. The evidence tables have
been extensively revised and updated. All recommendations
are thus based on either this evidence from observational
studies or on the expert consensus of the committee.
The definition of echocardiography used in this document
incorporates Doppler analysis, M-mode echocardiography,
two-dimensional transthoracic echocardiography (TTE), and,
when indicated, TEE. Intravascular ultrasound is not consid-
ered but is reviewed in the ACC/AHA Guidelines for Percu-
taneous Coronary Intervention (1) (available at http://www.
acc.org/clinical/guidelines/percutaneous/dirIndex.htm) and
the Clinical Expert Consensus Document on intravascular
ultrasound (2) (available at http://www.acc.org/clinical/con-
sensus/standards/standard12.htm). Echocardiography for
evaluating the patient with cardiovascular disease for noncar-
diac surgery is considered in the ACC/AHA Guidelines for
Perioperative Cardiovascular Evaluation for Noncardiac Sur-
gery (3). The techniques of three-dimensional echocardiog-
raphy are still in the developmental stages and are not
considered here. New techniques that are still rapidly evolv-
ing and improvements that are purely technological in echo-
Doppler instrumentation, such as color Doppler imaging and
digital echocardiography, are not going to be separately
discussed in the clinical recommendations addressed in this
document. Tissue Doppler imaging, both pulsed and color,
which detects low Doppler shift frequencies of high energy
generated by the contracting myocardium and consequent
wall motion, are proving very useful in evaluating systolic
and diastolic myocardial function. However, these technolog-
ical advances will also not be separately discussed in the
clinical recommendations (4,5). Echocardiographic-contrast
injections designed to assess myocardial perfusion to quantify
myocardium at risk and perfusion beds also were not
addressed.
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These guidelines address recommendations about the fre-
quency with which an echocardiographic study is repeated. If
the frequency with which studies are repeated could be
decreased without adversely affecting the quality of care, the
economic savings realized would likely be significant. With a
noninvasive diagnostic study and no known complications,
the potential for repeating the study unnecessarily exists. It is
easier to state when a repeat echocardiogram is not needed
then when and how often it should be repeated, because no
studies in the literature address this question. How often an
echocardiogram should be done depends on the individual
patient and must be left to the judgment of the physician until
evidence-based data addressing this issue are available.
The ACC/AHA/ASE 2003 Guideline Update for the Clin-
ical Application of Echocardiography includes several signif-
icant changes in the recommendations and in the supporting
narrative portion. In this summary, we list the updated
recommendations, as well as commentary on some of the
changes. All new or revised language in recommendations
appears in boldface type. Only the references supporting the
new recommendations are included in this article. The reader
is referred to the full-text version of the guidelines posted on
the American College of Cardiology (www.acc.org), Ameri-
can Heart Association (www.americanheart.org), and Amer-
ican Society for Echocardiography (www.asecho.org) World
Wide Web sites for a more detailed exposition of the rationale
for these changes.
Section II-B. Native Valvular Stenosis
Recommendations for Echocardiography in
Valvular Stenosis
Comment: New references (6,7).
Class IIb
2. Dobutamine echocardiography for the evaluation of
patients with low-gradient aortic stenosis and ven-
tricular dysfunction.
Section II-C. Native Valvular Regurgitation
Recommendations for Echocardiography in Native
Valvular Regurgitation
Comment: Literature on valvular effects of anorectic drugs
and references to echocardiographic predictors of prognosis
after aortic and mitral valve surgery have been added (6–10).
Class I
7. Assessment of the effects of medical therapy on the
severity of regurgitation and ventricular compensation
and function when it might change medical
management.
8. Assessment of valvular morphology and regurgita-
tion in patients with a history of anorectic drug use,
or the use of any drug or agent known to be
associated with valvular heart disease, who are
symptomatic, have cardiac murmurs, or have a
technically inadequate auscultatory examination.
Class III
2. Routine repetition of echocardiography in past users
of anorectic drugs with normal studies or known
trivial valvular abnormalities.
Section II-F. Infective Endocarditis:
Native Valves
Recommendations for Echocardiography in
Infective Endocarditis: Native Valves
Comment: The Duke Criteria for the diagnosis of infective
endocarditis have been added, as well as the value of TEE in
the setting of a negative transthoracic echocardiogram when
there is high clinical suspicion or when a prosthetic valve is
involved (11,12).
Class I
6. If TTE is equivocal, TEE evaluation of staphylococ-
cus bacteremia without a known source.
Class IIa
1. Evaluation of persistent nonstaphylococcus bactere-
mia without a known source.*
Class III
1. Evaluation of transient fever without evidence of
bacteremia or new murmur.
*TEE may frequently provide incremental value in addition to informa-
tion obtained by TTE. The role of TEE in first-line examination awaits
further study.
Section II-G. Prosthetic Valves
Recommendations for Echocardiography in
Valvular Heart Disease and Prosthetic Valves
Class I
3. Use of echocardiography (especially TEE) in guiding
the performance of interventional techniques and
surgery (eg, balloon valvotomy and valve repair) for
valvular disease.
Section IV-A. Acute Ischemic Syndromes
Recommendations for Echocardiography in the
Diagnosis of Acute Myocardial Ischemic
Syndromes
Comment: Movement of a recommendation from Class IIa to
Class I and minor wording change.
Recommendations for Echocardiography in Risk
Assessment, Prognosis, and Assessment of Therapy
in Acute Myocardial Ischemic Syndromes
Class I
4. Assessment of myocardial viability when required to
define potential efficacy of revascularization.*
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Class IIa
2. Moved to Class I (see above).
Class IIb
1. Assessment of late prognosis (greater than or equal to 2
years after acute myocardial infarction).
*Dobutamine stress echocardiography.
Section IV-B. Chronic Ischemic Heart Disease
Recommendations for Echocardiography in
Diagnosis and Prognosis of Chronic Ischemic
Heart Disease
Comment: There are new sections on stress echocardiography
in the detection of coronary disease in the transplanted heart
and stress echocardiography in the detection of coronary
disease in women. There is one new Class I recommendation
and three new Class IIa recommendations. Recommendations
have been renumbered for clarity.
Class I
2. Exercise echocardiography for diagnosis of myo-
cardial ischemia in selected patients (those for
whom ECG assessment is less reliable because of
digoxin use, LVH or with more than 1 mm ST
depression at rest on the baseline ECG, those with
pre-excitation [Wolff-Parkinson-White] syndrome,
complete left bundle-branch block) with an inter-
mediate pretest likelihood of CAD.
Class IIa
1. Prognosis of myocardial ischemia in selected pa-
tients (those in whom ECG assessment is less reli-
able) with the following ECG abnormalities: pre-
excitation (Wolff-Parkinson-White) syndrome,
electronically paced ventricular rhythm, more than
1 mm of ST depression at rest, complete left bundle-
branch block.*
2. Detection of coronary arteriopathy in patients who
have undergone cardiac transplantation.†
3. Detection of myocardial ischemia in women with a
low or intermediate pretest likelihood of CAD.*
Class IIb
1. Moved to Class IIa.
*Exercise or pharmacological stress echocardiogram.
†Dobutamine stress echocardiogram.
Recommendations for Echocardiography in
Assessment of Interventions in Chronic Ischemic
Heart Disease
One new Class IIa recommendation has been added.
Class IIa
1. Assessment of LV function in patients with previous
myocardial infarction when needed to guide possible
implantation of implantable cardioverter-
defibrillator (ICD) in patients with known or sus-
pected LV dysfunction.
Tables 1 through 6 are new tables that relate to CAD.
Section V-B. Regional LV Function
Recommendations for Echocardiography in Patients
With Dyspnea, Edema, or Cardiomyopathy
Class I
1. Dyspnea with clinical signs of heart disease.
Class IIb
1. Re-evaluation of patients with established cardiomyop-
athy when there is no change in clinical status but when
the results might change management.
Class III
2. Routine re-evaluation in clinically stable patients in
whom no change in management is contemplated and
for whom the results would not change management.
Section IX. Pulmonary Disease
Recommendations for Echocardiography in
Pulmonary and Pulmonary Vascular Disease
Comment: One recommendation was moved from Class I to
Class IIa. Class IIa recommendations have been renumbered
for clarity. Evidence was added concerning the diagnosis of
severe pulmonary embolism by echocardiography (122).
Class I
2. Moved to Class IIa (see below).
Class IIa
1. Pulmonary emboli and suspected clots in the right
atrium or ventricle or main pulmonary artery
branches.*
*TEE is indicated when TTE studies are not diagnostic.
Section XII. Arrhythmias and Palpitations
Recommendations for Echocardiography in
Patients With Arrhythmias and Palpitations
Comment: An additional Class IIb recommendation was
made concerning the use of echocardiography in the Maze
procedure (123–129).
Class IIa
2. TEE or intracardiac ultrasound guidance of radiofre-
quency ablative procedures.
Class IIb
3. Postoperative evaluation of patients undergoing the
Maze procedure to monitor atrial function.
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Recommendations for Echocardiography
Before Cardioversion
Class IIb
2. Patients with mitral valve disease or hypertrophic car-
diomyopathy who have been on long-term anticoagula-
tion at therapeutic levels before cardioversion unless
there are other reasons for anticoagulation (eg, prior
embolus or known thrombus on previous TEE).*
*TEE only.
Class III
2. Patients who have been on long-term anticoagulation at
therapeutic levels and who do not have mitral valve
disease or hypertrophic cardiomyopathy before cardio-
version unless there are other reasons for anticoag-
ulation (eg, prior embolus or known thrombus on
previous TEE).*
*TEE only.
Section XIIa. Screening
Recommendations for Echocardiography to Screen
for the Presence of Cardiovascular Disease
Comment: A section has been added on the molecular
genetics work that has identified a familial basis for many
forms of cardiomyopathy, including dilated congestive car-
diomyopathy, hypertrophic cardiomyopathy, and right ven-
tricular (RV) dysplasia. A possible genetic basis for these
cardiomyopathies supports echocardiographic screening of
first-degree relatives (130–138).
TABLE 1. Evaluation of Myocardial Viability With DSE in Patients With Chronic CAD and Impaired Systolic LV Function to Detect
Hibernating Myocardium
First Author, Year Ref. Stress
Total
Patients Criteria
Sensitivity
%
Specificity
%
PPV
%
NPV
%
Accuracy
%
Marzullo, 1993 13 LD-DSE 14 Imp. WM* 82 92 95 73 85
Cigarroa, 1993 14 LD-DSE 25 Imp. WM† 82 86 82 86 84
Alfieri, 1993 15 LD-DSE 14 Imp. WM* 91 78 92 76 88
La Canna, 1994 16 LD-DSE 33 Imp. WM* 87 82 90 77 85
Charney, 1994 17 LD-DSE 17 Imp. WM* 71 93 92 74 81
Afridi, 1995 18 DSE 20 Imp. WM† 80 90 89 82 85
Perrone-Filardi, 1995 19 LD-DSE 18 Imp. WM* 88 87 91 82 87
Senior, 1995 20 LD-DSE 22 Imp. WM* 87 82 92 73 86
Haque, 1995 21 LD-DSE 26 Imp. WM* 94 80 94 80 91
Arnese, 1995 22 LD-DSE 38 Imp. WM* 74 96 85 93 91
deFilippi, 1995 23 LD-DSE 23 Imp. WM* 97 75 87 93 89
Iliceto, 1996 24 LD-DSE 16 Imp. WM* 71 88 73 87 83
Varga, 1996 25 LD-DSE 19 Imp. WM* 74 94 93 78 84
Baer, 1996 26 LD-DSE 42 Imp. WM† 92 88 92 88 90
Vanoverschelde, 1996 27 LD-DSE 73 Imp. WM† 88 77 84 82 84
Gerber, 1996 28 LD-DSE 39 Imp. WM* 71 87 89 65 77
Bax, 1996 29 LD-DSE 17 Imp. WM* 85 63 49 91 70
Perrone-Filardi, 1996 30 LD-DSE 18 Imp. WM* 79 83 92 65 81
Qureshi, 1997 31 LD-DSE 34 Imp. WM* 86 68 51 92 73
Qureshi, 1997 31 DSE 34 Biphasic resp* 74 89 72 89 85
Nagueh, 1997 32 LD-DSE 18 Imp. WM* 91 66 61 93 75
Nagueh, 1997 32 DSE 18 Biphasic resp* 68 83 70 82 77
Furukawa, 1997 33 LD-DSE 53 Imp. WM* 79 72 76 75 76
Cornel, 1997 34 LD-DSE 30 Imp. WM* 89 82 74 93 85
DSE indicates dobutamine stress echocardiography (dobutamine infused at both low and high doses); CAD, coronary artery disease; LV, left ventricular; Ref.
reference number; Stress, DSE protocol used for pharmacological stress; Total Patients, number of patients with chronic CAD and LV dysfunction in whom
DSE studies were analyzed; Criteria, findings on DSE considered as a “positive” indicator of viability; PPV, positive predictive value (likelihood that presence of viability by DSE
is indicative of subsequent functional recovery after revascularization); NPV, negative predictive value (likelihood that absence of viability by DSE is indicative of lack of functional
recovery after revascularization); LD-DSE, low dose DSE; Imp. WM, improved wall motion during dobutamine stress in a previously asynergic segment; and Biphasic resp,
biphasic response, defined as improvement in wall motion during LD-DSE followed by worsening at high dose.
In these patients, percutaneous or surgical revascularization was performed after DSE testing. Those patients demonstrating improved wall motion on follow-up
resting transthoracic echocardiography were considered to have had impaired LV function due to hibernating myocardium, whereas those demonstrating no
improvement despite revascularization were considered to have had impaired LV function due to necrotic myocardium.
*Wall motion analyzed by segment; †wall motion analyzed by patient.
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TABLE 2. Prognostic Value of Stress Echocardiography in Various Patient Populations*
Annualized Event Rate, %
First Author, Year Reference Stress Total Pts Avg F/U, mo Events Ischemia No Ischemia Normal
Chronic ischemic heart disease
Picano, 1989 35 DIP† 539 36 D, MI 2.3 0.7   
Sawada, 1990 36 NL TME 148 28.4 D, MI       0.6
Mazeika, 1993 37 DSE† 51 24 D, MI, UA 16 3.8   
Krivokapich, 1993 38 TME† 360 12 D, MI 10.8 3.1   
Afridi, 1994 39 DSE† 77 10 D, MI 48 8.9 3
Poldermans, 1994 40 DSE† 430 17 D, MI 6.6 3.4   
Coletta, 1995 41 DIP† 268 16 D, MI 17.9 1.4   
Kamaran, 1995 42 DSE† 210 8 D, MI 69 1   
Williams, 1996 43 DSE† 108 16 D, MI, Re 32.6 7.3   
Anthopoulos, 1996 44 DSE† 120 14 D, MI 13.6 0   
Marcovitz, 1996 45 DSE† 291 15 D, MI 12.8 8.2 1.1
Heupler, 1997 46 TME† 508w 41 D, MI, Re 9.2 1.3   
McCully, 1998 47 NL TME 1325 23 D, MI       0.5
Chuah, 1998 48 DSE‡ 860 24 D, MI 6.9 6.3 1.9
Cortigiani, 1998 49 DSE or DIP† 456w 32 D, MI 2.9 0.3   
Davar, 1999 50 NL DSE 72w 13 D, MI       0
After cardiac transplantation
Ciliberto, 1993 51 DIP‡ 80 9.8 D, MI, CHF 26.2 0   
Lewis, 1997 52 DSE‡ 63 8 D, MI, CHF 28.6 3.6   
Annualized Event Rate indicates the percentage of patients per year who developed at least 1 adverse event during follow-up, depending on whether inducible
ischemia was or was not demonstrated by stress echocardiography (the annualized event rate is also tabulated for those series describing patients who had normal
resting and normal stress results); Stress, stress echocardiography protocol; Total Pts, number of patients studied with stress echocardiography and subsequently
followed up for the development of adverse events (including death, nonfatal myocardial infarction, revascularization, or unstable angina; in posttransplant patients,
development of severe congestive heart failure was also considered an adverse event); Avg F/U, average period of follow-up after stress echocardiography; DIP,
dipyridamole stress echocardiography; D, death; MI, nonfatal myocardial infarction; NL, series describing follow-up only in subjects with normal stress
echocardiography test results; TME, treadmill stress echocardiography; DSE, dobutamine stress echocardiography; UA, unstable angina; Re, revascularization
necessary; w, patients in these series were all women; and CHF, development of severe congestive heart failure.
*Prognostic value of inducible ischemia, detected with different forms of stress echocardiography, in patients with chronic ischemic heart disease and patients after
cardiac transplantation.
†New wall motion abnormality considered “positive” for inducible ischemia.
‡Any wall motion abnormality (at rest or with stress) considered “positive.”
TABLE 3. Prognostic Value of Viable (Hibernating) Myocardium by LD-DSE and Influence of Revascularization
First Author, Year Ref. Stress Total Pts Avg F/U, mo Adverse Events
Annualized Event Rate, %
Viable, Re Viable, Re Not Viable
Meluzin, 1998 53 LD-DSE 133 20 Death, MI 4.1    9.5
Afridi, 1998 54 LD-DSE 353 18 Death 4 20 19
LD-DSE indicates low-dose dobutamine stress echocardiography; Ref., reference number; Stress, stress echocardiography protocol; Total Pts, number of patients
with chronic ischemic heart disease and impaired left ventricular systolic function studied with LD-DSE and subsequently followed up for the development of an
adverse event (death or nonfatal myocardial infarction); Avg F/U, average period of follow-up after LD-DSE; Annualized Event Rate, percentage of patients per year
who developed an adverse event during follow-up after LD-DSE; Viable, Re, patients with viability (contractile reserve) demonstrated by LD-DSE who underwent
revascularization and were then followed up; Viable, -Re, patients with viability (contractile reserve) demonstrated by LD-DSE who did not undergo revascularization
and were then followed up; Not Viable, patients without contractile reserve by LD-DSE who were followed up for adverse events; and MI, nonfatal myocardial infarction.
Prognostic value of contractile reserve detected with LD-DSE in patients with chronic ischemic heart disease and impaired left ventricular systolic function. The
annualized rate of death or MI is tabulated in patients with viable myocardium by LD-DSE depending on whether they did or did not undergo revascularization and
also in those patients without viable myocardium.
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Class I
5. First-degree relatives (parents, siblings, children) of
patients with unexplained dilated cardiomyopathy in
whom no etiology has been identified.
Class III
2. Routine screening echocardiogram for participation
in competitive sports in patients with normal cardio-
vascular history, ECG, and examination.
Section XIII. Echocardiography in the
Critically Ill
Recommendations for Echocardiography in the
Critically Ill
Comment: This section has been revised extensively. A
discussion has been added on the echocardiographic detection
of pulmonary embolism and the usefulness of TEE versus
TTE in the critically ill patient. A section on the value of
echocardiography in blunt aortic trauma has also been added.
TABLE 4. Diagnostic Accuracy of Exercise Echocardiography in Detecting Angiographically Proved CAD (Without Correction for
Referral Bias)
First Author, Year Ref. Exercise Significant CAD
Total
Pts
Sensitivity,
%
Sens 1-VD,
%
Sens MVD,
%
Specificity,
%
PPV,
%
NPV,
%
Accuracy,
%
Limacher, 1983 55 TME Greater than 50% 73 91 64 98 88 96 75 90
Armstrong, 1986 56 TME Greater than or equal to 50% 95 88       87 97 57 87
Armstrong, 1987 57 TME Greater than or equal to 50% 123 88 81 93 86 97 61 88
Ryan, 1988 58 TME Greater than or equal to 50% 64 78 76 80 100 100 73 86
Labovitz, 1989 59 TME Greater than or equal to 70% 56 76       100 100 74 86
Sawada, 1989 60 TME or UBE Greater than or equal to 50% 57 86 88 82 86 86 86 86
Sheikh, 1990 61 TME Greater than or equal to 50% 34 74 74    91 94 63 79
Pozzoli, 1991 62 UBE Greater than or equal to 50% 75 71 61 94 96 97 64 80
Crouse, 1991 63 TME Greater than or equal to 50% 228 97 92 100 64 90 87 89
Galanti, 1991 64 UBE Greater than or equal to 70% 53 93 93 92 96 96 93 94
Marwick, 1992 65 TME Greater than or equal to 50% 150 84 79 96 86 95 63 85
Quinones, 1992 66 TME Greater than or equal to 50% 112 74 59 89 88 96 51 78
Salustri, 1992 67 BE Greater than or equal to 50% 44 87 87    85 93 75 86
Amanullah, 1992 68 UBE Greater than or equal to 50% 27 82       80 95 50 81
Hecht, 1993 69 SBE Greater than or equal to 50% 180 93 84 100 86 95 79 91
Ryan, 1993 70 UBE Greater than or equal to 50% 309 91 86 95 78 90 81 87
Mertes, 1993 71 SBE Greater than or equal to 50% 79 84 87 89 85 91 75 85
Hoffmann, 1993 72 SBE Greater than 70% 66 80 79 81 88 95 58 82
Cohen, 1993 73 SBE Greater than 70% 52 78 63 90 87 94 62 81
Marwick, 1994 74 BE Greater than 50% 86 88 82 91 80 89 77 85
Roger, 1994 75 TME Greater than or equal to 50% 150 91                  
Marangelli, 1994 76 TME Greater than or equal to 75% 80 89 76 97 91 93 86 90
Beleslin, 1994 77 TME Greater than or equal to 50% 136 88 88 91 82 97 50 88
Williams, 1994 78 UBE Greater than 50% 70 88 89 86 84 83 89 86
Roger, 1995 79 TME Greater than or equal to 50% 127 88       72 93 60   
Dagianti, 1995 80 SBE Greater than 70% 60 76 70 80 94 90 85 87
Marwick, 1995 81 TME or UBE Greater than or equal to 50% 161 80 75 85 81 71 91 81
Bjornstad, 1995 82 UBE Greater than or equal to 50% 37 84 78 86 67 93 44 81
Marwick, 1995 83 TME Greater than 50% 147 71 63 80 91 85 81 82
Tawa, 1996 84 TME Greater than 70% 45 94       83 94 83 91
Luotolahti, 1996 85 UBE Greater than or equal to 50% 118 94 94 93 70 97 50 92
Tian, 1996 86 TME Greater than 50% 46 88 91 86 93 97 76 89
Roger, 1997 87 TME Greater than or equal to 50% 340 78       41 79 40 69
CAD indicates coronary artery disease; Ref., reference number; Exercise, type of exercise testing used in conjunction with transthoracic echocardiographic imaging;
Significant CAD, % coronary luminal diameter narrowing, demonstrated by selective coronary angiography, considered to represent significant CAD; Total Pts, number
of patients in each series undergoing selective coronary angiography in whom exercise echocardiographic studies and wall motion analysis were also performed; Sens
1-VD, test results positive in patients with single-vessel CAD; Sens MVD, test results positive in patients with multivessel disease; PPV, positive predictive value
(likelihood of angiographically significant CAD in patients with inducible wall motion abnormalities by exercise echocardiography); NPV, negative predictive value
(likelihood of absence of angiographically significant CAD in patients without inducible wall motion abnormalities by exercise echocardiography); TME, treadmill
exercise; UBE, upright bicycle ergometry; BE, bicycle ergometry; and SBE, supine bicycle ergometry.
A new or worsening regional wall motion abnormality induced by stress generally was considered a “positive” result.
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TABLE 5. Diagnostic Accuracy of Dobutamine Stress Echocardiography in Detecting Angiographically Proved CAD (Without
Correction for Referral Bias)
Author, Year Ref. Protocol Significant CAD
Total
Pts
Sensitivity,
%
Sens 1-VD,
%
Sens MVD,
%
Specificity,
%
PPV,
%
NPV,
%
Accuracy,
%
Berthe, 1986 88 DSE 5–40 Greater than or equal to 50% 30 85    85 88 85 88 87
Sawada, 1991 89 DSE 2.5–30 Greater than or equal to 50% 55 89 81 100 85 91 81 74
Sawada, 1991 89 DSE 2.5–30 Greater than or equal to 50% 41 81    81 87 91 72 87
Previtali, 1991 90 DSE 5–40 Greater than or equal to 70% 35 68 50 92 100 100 44 83
Cohen, 1991 91 DSE 2.5–40 Greater than 70% 70 86 69 94 95 98 72 89
Martin, 1992 92 DSE 10–40 Greater than 50% 34 76       44 79 40 68
McNeill, 1992 93 DASE 10–40 Greater than or equal to 50% 28 71                71
Segar, 1992 94 DSE 5–30 Greater than or equal to 50% 88 95       82 94 86 92
Mazeika, 1992 95 DSE 5–20 Greater than or equal to 70% 50 78 50 92 93 97 62 82
Marcovitz, 1992 96 DSE 5–30 Greater than or equal to 50% 141 96 95 98 66 91 84 89
McNeill, 1992 97 DASE 10–40 Greater than or equal to 50% 80 70       88 89 67 78
Salustri, 1992 98 DSE 5–40 Greater than or equal to 50% 46 79       78 85 70 78
Marwick, 1993 99 DSE 5–40 Greater than or equal to 50% 97 85 84 86 82 88 78 84
Forster, 1993 100 DASE 10–40 Greater than 50% 21 75 - - 89 90 73 81
Gunalp, 1993 101 DSE 5–30 Greater than 50% 27 83 78 89 89 94 73 85
Marwick, 1993 102 DSE 5–40 Greater than or equal to 50% 217 72 66 77 83 89 61 76
Hoffmann, 1993 72 DASE 5–40 Greater than 70% 64 79 78 81 81 93 57 80
Previtali, 1993 103 DSE 5–40 Greater than 50% 80 79 63 91 83 92 61 80
Takeuchi, 1993 104 DSE 5–30 Greater than or equal to 50% 120 85 73 97 93 95 80 88
Cohen, 1993 73 DSE 2.5–40 Greater than 70% 52 86 75 95 87 94 72 87
Ostojic, 1994 105 DSE 5–40 Greater than or equal to 50% 150 75 74 81 79 96 31 75
Marwick, 1994 74 DSE 5–40 Greater than 50% 86 54 36 65 83 86 49 64
Beleslin, 1994 77 DSE 5–40 Greater than or equal to 50% 136 82 82 82 76 96 38 82
Sharp, 1994 106 DSE 5–50 Greater than or equal to 50% 54 83 69 89 71 89 59 80
Pellikka, 1995 107 DSE 5–40 Greater than or equal to 50% 67 98       65 84 94 87
Ho, 1995 108 DSE 5–40 Greater than or equal to 50% 54 93 100 92 73 93 73 89
Daoud, 1995 109 DSE 5–30 Greater than or equal to 50% 76 92 91 93 73 95 62 89
Dagianti, 1995 80 DSE 5–40 Greater than or equal to 70% 60 72 60 80 97 95 83 87
Pingitore, 1996 110 DASE 5–40 Greater than or equal to 50% 110 84 78 88 89 97 52 85
Schroder, 1996 111 DASE 10–40 Greater than or equal to 50% 46 76 71 90 88 97 44 78
Anthopoulos, 1996 44 DASE 5–40 Greater than or equal to 50% 120 87 74 90 84 94 68 86
Ling, 1996 112 DASE 5–40 Greater than or equal to 50% 183 93       62 95 54 90
Takeuchi, 1996 113 DASE 5–40 Greater than or equal to 50% 70 75 78 73 92 79 90 87
Minardi, 1997 114 DASE 5–40 Greater than or equal to 50% 47 75 81 67 67 97 15 74
Dionisopoulos, 1997 115 DASE 5–40 Greater than or equal to 50% 288 87 80 91 89 95 71 87
Elhendy, 1997 116 DASE 5–40 Greater than or equal to 50% 306 74 59 83 85 94 50 76
Ho, 1998 117 DSE 5–40 Greater than or equal to 50% 51 93 89 95 82 87 90 88
CAD indicates coronary artery disease; Ref., reference number; Protocol, dobutamine stress protocol, including initial and peak infusion rates (expressed in micrograms per
kilogram per minute); Significant CAD, % coronary luminal diameter narrowing, demonstrated by selective coronary angiography, considered to represent significant CAD; Total
Pts, number of patients in each series undergoing selective coronary angiography in whom dobutamine stress echocardiographic studies and wall motion analysis were also
performed; Sens 1-VD, test results positive in patients with single-vessel CAD; Sens MVD, test results positive in patients with multivessel CAD; PPV, positive predictive value
(likelihood of angiographically significant CAD in patients with inducible wall motion abnormalities by pharmacological stress echocardiography); NPV, negative predictive value
(likelihood of absence of angiographically significant CAD in patients without inducible wall motion abnormalities by pharmacological stress echocardiography); DSE,
dobutamine stress echocardiography; and DASE, dobutamine/atropine stress echocardiography.
A new or worsening regional wall motion abnormality induced by stress generally was considered a “positive” result.
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The evidence tables have been extensively revised and
updated (139–164).
Class III
1. Suspected myocardial contusion in the hemodynam-
ically stable patient with a normal ECG who has no
abnormal cardiac/thoracic physical findings and/or
lacks a mechanism of injury that suggests cardiovas-
cular contusion.
Section XIV. Two-Dimensional
Echocardiography in the Adult Patient With
Congenital Heart Disease
Recommendations for Echocardiography in the
Adult Patient With Congenital Heart Disease
Comment: A section has been added on the accuracy of echocar-
diography to allow surgery to proceed without catheterization in
some congenital heart lesions. Echocardiography is useful in the
performance of interventional therapeutic procedures (165–177).
Class I
5. Patients with known congenital heart disease in
whom it is important that pulmonary artery pressure
be monitored (eg, patients with hemodynamically
important, moderate, or large ventricular septal
defects, atrial septal defects, single ventricle, or any
of the above with an additional risk factor for
pulmonary hypertension).
6. Periodic echocardiography in patients with repaired
(or palliated) congenital heart disease with the fol-
lowing: change in clinical condition or clinical sus-
picion of residual defects, obstruction of conduits
and baffles, or LV or RV function that must be
monitored, or when there is a possibility of hemody-
namic progression or a history of pulmonary
hypertension.
8. Identification of site of origin and initial course of
coronary arteries (TEE may be indicated in some
patients).*
*TEE may be necessary to image both coronary origins in adults.
Section XV-E. Acquired Cardiovascular
Disease in the Neonate
Recommendations for Neonatal Echocardiography
Comment: Only minor changes have been made in this
section. Two new Class I recommendations and one Class III
recommendation have been added (177–194). One recom-
TABLE 6. Diagnostic Accuracy of Stress Echocardiography in Detecting Angiographically Proved CAD in Women (Generally Without
Correction for Referral Bias)
First Author, Year Ref. Protocol Significant CAD
Total
Pts
Sensitivity,
%
Sens 1-VD,
%
Sens MVD,
%
Specificity,
%
PPV,
%
NPV,
%
Accuracy,
%
Masini, 1988 118 DIP Greater than or equal to 70% 83 79       93 91 84 87
Sawada, 1989 60 TME or UBE Greater than or equal to 50% 57 86 88 82 86 86 86 86
Severi, 1994 119 DIP Greater than or equal to 75% 122 68       96 90 86 87
Williams, 1994 78 UBE Greater than 50% 70 88 89 86 84 83 89 86
Marwick, 1995 81 TME or UBE Greater than or equal to 50% 161 80 75 85 81 71 87 81
Takeuchi, 1996 113 DASE Greater than or equal to 50% 70 75 78 73 92 79 90 87
Roger, 1997 87 TME or UBE Greater than or equal to 50% 96 79       37 66 54 63
Dionisopoulos, 1997 115 DASE Greater than or equal to 50% 101 90 79 94 79 90 79 86
Laurienzo, 1997 120 DS-TEE Greater than or equal to 70% 84 82       100 100 94 95
Elhendy, 1997 116 DASE Greater than or equal to 50% 96 76 64 92 94 96 68 82
Ho, 1998 117 DSE Greater than or equal to 50% 51 93 89 95 82 87 90 88
Studies accounting for referral bias
Lewis, 1999
(by design)
121 DSE Greater than or equal to 50% 92 40 40 60*
82†
81 71 84 70
Roger, 1997
(by adjustment)
87 TME Greater than or equal to 50% 1714 32 24 31 (2V)
43 (3V)
86 66
CAD indicates coronary artery disease; Ref., reference number; Protocol, exercise or pharmacological protocol used in conjunction with transthoracic
echocardiographic imaging; Significant CAD, % coronary luminal diameter narrowing, documented by selective coronary angiography, considered to represent
significant CAD; Total Pts, number of women in each series undergoing selective coronary angiography in whom stress echocardiographic studies and wall motion
analysis were also performed; Sens 1-VD, test results positive in patients with single-vessel CAD; Sens MVD, test results positive in patients with multivessel CAD;
PPV, positive predictive value (likelihood of angiographically significant CAD in patients with inducible wall motion abnormalities by stress echocardiography); NPV,
negative predictive value (likelihood of absence of angiographically significant CAD in patients without inducible wall motion abnormalities by stress echocardiography);
DIP, dipyridamole stress echocardiography; TME, treadmill stress echocardiography; UBE, upright bicycle stress echocardiography; DASE, dobutamine/atropine stress
echocardiography; DS-TEE, dobutamine stress transesophageal echocardiography; and DSE, dobutamine stress echocardiography.
A new or worsening regional wall motion abnormality induced by stress generally was considered a “positive” result.
*Including all patients.
†Excluding patients with indeterminate studies.
962 Cheitlin et al. JACC Vol. 42, No. 5, 2003
Update to Guidelines for Clinical Echocardiography September 3, 2003:954–70
mendation has moved from Class IIb to Class IIa. Class I
recommendations have been renumbered for clarity.
Class I
12. Re-evaluation after initiation or termination of med-
ical therapy for pulmonary artery hypertension.
13. Re-evaluation during initiation or withdrawal of
extracorporeal cardiopulmonary support.
Class IIa
3. Presence of a syndrome associated with a high
incidence of congenital heart disease for which there
are no abnormal cardiac findings and no urgency of
management decisions.
Class IIb
1. Moved to Class IIa (see above).
Class III
2. Acrocyanosis with normal upper- and lower-
extremity pulsed oximetry oxygen saturations.
Section XV-F. Congenital Cardiovascular
Disease in the Infant, Child, and Adolescent
Recommendations for Echocardiography in the
Infant, Child, and Adolescent
Comment: There are two new Class I recommendations,
which have been renumbered for clarity (6,195–200).
Class I
5. Selection, placement, patency, and monitoring of
endovascular devices, as well as identification of
intracardiac or intravascular shunting before, dur-
ing, and subsequent to interventional cardiac
catheterization.
6. Immediate assessment after percutaneous interven-
tional cardiac catheterization procedure.
10. Presence of a syndrome associated with cardiovascular
disease and dominant inheritance or multiple affected
family members (eg, Marfan syndrome or Ehlers-
Danlos syndrome).
Deleted:
Phenotypic findings of Marfan syndrome or Ehlers-Danlos
syndrome.
Presence of a syndrome associated with high incidence of
congenital heart disease when there are no abnormal
cardiac findings.
“Atypical,” “nonvasodepressor” syncope without other
causes.
Section XV-G. Arrhythmias/Conduction
Disturbances
Recommendations for Echocardiography in
Pediatric Patients With Arrhythmias/Conduction
Disturbances
Comment: Echocardiography is discretionary after radiofre-
quency catheter ablation. Persistent ventricular dilatation
after successful ablation or effective medical control of the
heart rate may indicate an arrhythmogenic primary cardio-
myopathy (201–203).
Class IIa
2. Evidence of pre-excitation on ECG with symptoms.
Class IIb
3. Examination immediately after radiofrequency
ablation.
Section XV-H. Acquired Cardiovascular
Disease
Recommendations for Echocardiography in
Pediatric Acquired Cardiovascular Disease
Comment: The leading cause of death after the first posttrans-
plant year is transplant-related CAD. There is evidence that
stress echocardiography identifies subclinical ischemia
(204–213).
Class I
3. Baseline and re-evaluation examinations of patients
receiving cardiotoxic chemotherapeutic agents.
5. Patients with severe renal disease and/or systemic
hypertension.
Class III
1. Routine screening echocardiogram for participation
in competitive sports in patients with normal cardio-
vascular examination.
Section XV-I. Pediatric Acquired
Cardiopulmonary Disease
Recommendations for Echocardiography in
Pediatric Acquired Cardiopulmonary Disease
Comment: Echocardiography provides documentation of pul-
monary artery hypertension and estimation of severity by the
presence of RV dilation and/or hypertrophy, the presence of
tricuspid or pulmonic valvular regurgitation, and Doppler
estimation of RV systolic pressure (214,215).
Class I
2. Re-evaluation after surgical intervention or initia-
tion of oral and/or parenteral vasodilator therapy
for pulmonary artery hypertension.
3. Re-evaluation during withdrawal of extracorporeal
cardiopulmonary support.
Section XV-K. Transesophageal
Echocardiography
Recommendations for TEE in Pediatric Patients
Comment: TEE has become particularly helpful in guiding
placement of catheter-deployed devices used in closing atrial
septal defects. It is essential in ensuring proper positioning of
the device in the defect and assessing for residual shunts and
abnormal device occlusion of venous inflow into the atria or
encroachment on the atrioventricular valves. Likewise, place-
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ment of catheters for radiofrequency ablation of arrhythmo-
genic pathways can be facilitated by TEE when there are
intracardiac abnormalities (216–222).
Class I
2. Monitoring and guidance during cardiothoracic surgi-
cal procedures.
8. Patients with right atrial to pulmonary artery Fon-
tan connection, for identification of atrial thrombus.
Class IIa
1. Patients with lateral tunnel Fontan palliation.
Section XVI. Intraoperative
Echocardiography
Recommendations for Intraoperative
Echocardiography
Comment: This section is new. In 1996, a task force of the
American Society of Anesthesiologists/Society of Cardiovas-
cular Anesthesiologists (ASA/SCA) published practice
guidelines for perioperative TEE. The guidelines were evi-
dence based and focused on the effectiveness of perioperative
TEE in improving clinical outcomes. A literature search
conducted at that time retrieved 1844 articles, of which 588
were considered relevant to the perioperative setting. A more
recent literature search identified an additional 118 articles
related to the intraoperative use of echocardiography. The
current text makes reference only to the latter. However, the
indications for intraoperative echocardiography that are pro-
vided in these guidelines are based on both the initial
ASA/SCA guidelines and the newer information (223–260).
For a detailed discussion of this topic, please see the
full-text version of the guidelines posted on the ACC, AHA,
and American Society of Echocardiography (ASE) World
Wide Web sites.
Class I
1. Evaluation of acute, persistent, and life-threatening
hemodynamic disturbances in which ventricular
function and its determinants are uncertain and
have not responded to treatment.
2. Surgical repair of valvular lesions, hypertrophic
obstructive cardiomyopathy, and aortic dissection
with possible aortic valve involvement.
3. Evaluation of complex valve replacements requiring
homografts or coronary reimplantation, such as the
Ross procedure.
4. Surgical repair of most congenital heart lesions that
require cardiopulmonary bypass.
5. Surgical intervention for endocarditis when preop-
erative testing was inadequate or extension to peri-
valvular tissue is suspected.
6. Placement of intracardiac devices and monitoring of
their position during port-access and other cardiac
surgical interventions.
7. Evaluation of pericardial window procedures in
patients with posterior or loculated pericardial
effusions.
Class IIa
1. Surgical procedures in patients at increased risk of
myocardial ischemia, myocardial infarction, or he-
modynamic disturbances.
2. Evaluation of valve replacement, aortic atheroma-
tous disease, the Maze procedure, cardiac aneurysm
repair, removal of cardiac tumors, intracardiac
thrombectomy, and pulmonary embolectomy.
3. Detection of air emboli during cardiotomy, heart
transplant operations, and upright neurosurgical
procedures.
Class IIb
1. Evaluation of suspected cardiac trauma, repair of
acute thoracic aortic dissection without valvular
involvement, and anastomotic sites during heart
and/or lung transplantation.
2. Evaluation of regional myocardial function during
and after off-pump coronary artery bypass graft
procedures.
3. Evaluation of pericardiectomy, pericardial effusions,
and pericardial surgery.
4. Evaluation of myocardial perfusion, coronary anat-
omy, or graft patency.
5. Dobutamine stress testing to detect inducible de-
mand ischemia or to predict functional changes after
myocardial revascularization.
6. Assessment of residual duct flow after interruption
of patent ductus arteriosus.
Class III
1. Surgical repair of uncomplicated secundum atrial
septal defect.
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